Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Q1 2020/21 Earnings Presentation
76 slides from Coloplast A/s Class B's earnings presentation, February 2021
Slide 1: Making life easier
Making life easier You can do what you want to do. You build your life Tabitha Sustainable growth leadership Roadshow presentation Q1 2020/21 Making life easier Ostomy Care, Continence Care, Wound & Skin Care and Interventional Urology
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Q1 marks a good start to the year with 5% organic growth
Q1 marks a good start to the year with 5% organic growth – guidance for 2020/21 maintained Q1 2020/21 Highlights Revenue growth • Organic growth of 5% and 1% reported growth in DKK Reported revenue (DKKm) +5% • 6% organic growth in Chronic Care driven by solid performance in US Organic growth and Em
Slide 4: Growth in Q1 driven by Emerging markets and US
Growth in Q1 was driven by Emerging markets and US offset by lower growth in Europe due to COVID-19 Q1 20/21 revenue by business area Q1 20/21 revenue by geography Business Reported revenue Organic growth Geographic Reported revenue Organic growth Share of organic area DKKm area DKKm growth Ostomy C
Slide 5: Ostomy Care grew 6% organically in Q1
Ostomy Care grew 6% organically in Q1, adversely impacted by lower growth in new patients in Europe Ostomy Care performance Comments • Q1 organic growth of 6% (reported growth 1%) • Growth was driven by Emerging markets and the US but 10 10 negatively impacted by the decline in new patients across E
Slide 6: Continence Care grew 6% organically in Q1
Continence Care grew 6% organically in Q1, adversely impacted by lower growth in new patients across Europe Continence Care performance Comments • Q1 organic growth of 6% (reported growth 1%) 12 • Growth was driven by the US and Germany, but negatively impacted by lower growth in Europe and mainly t
Slide 7: Interventional Urology grew 5% organically in Q1
Interventional Urology grew 5% organically in Q1 as elective procedures continue to recover in the US and Europe Interventional Urology performance Comments • Q1 organic growth of 5% (0% reported growth) • Interventional Urology returned to growth as elective procedures continue to recover in the US
Slide 8: Wound Care delivered 5% organic growth in Q1
Wound Care delivered 5% organic growth in Q1 driven by Europe and return to growth in China Wound & Skin Care performance Comments • Q1 organic growth of 1% in Wound & Skin Care (-3% reported growth). 11 • Q1 organic growth was 5% for Wound Care driven by Europe and a 10 5 return to growth in China.
Slide 9: Q1 reported revenue increased by 1% due to currency depreciation
Q1 2020/21 reported revenue increased by 1% due to depreciation in USD, GBP and Emerging market currencies Comments Revenue development • Q1 2020/21 reported revenue increase by DKK 26m or (DKKm) 1% compared to Q1 2019/20 240 • Q1 organic growth of 5% or DKK 240m • Main drivers 4,712 4,738 − Solid g
Slide 10: EBIT margin of 32% in Q1
EBIT margin of 32% in Q1 driven by prudent cost management and lower travel & marketing spend Comments EBIT margin development (%) • Q1 gross margin of 68% in DKK on par with last year • Positive impact from GOP4 and GOP5 33.3 • Negative impact from salary inflation and labour shortages in 2.4 -0.3
Slide 11: FCF driven by solid underlying earnings and lower tax paid
FCF driven by solid underlying development in earnings and decrease in income tax paid FCF development Comments • Free cash flow in Q1 was an outflow of DKK 14m, compared to an inflow of DKK 816m last year 98 99 98 93 • Adjusted for the DKK 950m acquisition of Nine Continents Medical in 90 88 Novemb
Slide 12: Unchanged financial guidance for FY 2020/21
Unchanged financial guidance for FY 2020/21 Guidance 2020/21 Guidance 2020/21 (DKK)* Key assumptions • Phasing of growth expected to be back-end loaded with low single-digit growth in H1 and double-digit growth in H2 7-8% • Interventional Urology positively impacted by comparison period in 2019/20 S
Slide 13: Introduction to Coloplast
Making it easier to be yourself Leading intimate healthcare Introduction to Coloplast Stina Making life easier Ostomy Care, Continence Care, Wound & Skin Care and Interventional Urology
Slide 14: Coloplast has four business areas with global sales presence
Coloplast has four business areas all with global sales presence Group revenue 2019/20 by segment Group revenue 2019/20 by geography X = Coloplast’s global market position Emerging markets 17% Ostomy Care Continence 40% Care 37% #1 DKK DKK 18.5bn #1 18.5bn Other European developed markets markets 58
Slide 15: Coloplast specializes in intimate healthcare needs
Coloplast specializes in intimate healthcare needs Who are our typical users How do we help them? People who have had their intestine redirected to an SenSura® Mio opening in the abdominal wall Ostomy bag Ostomy Care People in need of bladder or bowel management SpeediCath® Continence Flexible male
Slide 16: The Chronic Care model secures a predictable revenue stream
The Chronic Care model secures a predictable revenue stream and stable revenue growth The chronic care user flow Chronic Care condition New user Installed base of users Stable flow of loyal users Solid reimbursement Coloplast group revenues Revenue (DKKbn) Organic growth (%) 10 10 9 8 8 8 8 7 7 7 7
Slide 17: Intimate healthcare is characterized by stable industry trends
Intimate healthcare is characterized by stable industry trends Drivers Limiters Earlier detection and Growing elderly Surgical and cure, eventually 1 Demographics population increases 1 medical trends reduces addressable customer base for market for Coloplast Coloplast products treatment products Ex
Slide 18: Strong market positions in Europe and potential outside Europe
Coloplast has strong market positions in Europe and great commercial potential outside Europe Europe Developed Emerging Ostomy Continence Urology Wound Care Addressable market 18-19n 14-15bn 11-12bn 22-24bn 4-5% 5-6% 3-5% 2-4% Size in DKK Growth in % Coloplast 40 - 50% 45 - 55% 20 - 25% 5 - 10% regi
Slide 19: Building the consumer healthcare company of the future
We are building the consumer healthcare company of the future Chronic Care Macro Trends Impact Commercial model Ageing population Superior, clinically differentiated products Healthcare consumerism Digital transformation Consumer preference Data and Clinical digital tools preference Price pressure P
Slide 20: Our new strategy will drive long-term value creation
Our new strategy will drive continued long-term value creation through revenue and earnings growth Chronic Care Interventional Wound & Urology Skin Care 7-9% more than30% organic growth p.a. EBIT margin1 Talent, Innovation Leadership & Culture Unparalleled Sustainability efficiency 1) Constant curre
Slide 21: Supporting sustainable development
Supporting sustainable development with a strong emphasis on improving our environmental performance Our mission Making life easier for people with intimate healthcare needs Our 2025 priority Our 2025 priority Reducing Improving emissions products and packaging 0 emissions from scope 1&2 80% packagi
Slide 22: Incremental investments of up to 2% of revenue
We will continue to support organic growth by yearly incremental investments of up to 2% of revenue Key Investment Decision Drivers Key Investment Areas ✓ We expect to invest up to 2% Economics & of revenue in incremental OPEX investments Government ✓ Innovation Market Attractiveness Chronic Care ✓
Slide 23: Actively pursue M&A opportunities
We will actively pursue M&A opportunities as a lever for long-term growth Opportunity based Systematic screening Channel Portfolio expansion Early stage Large plays expansion & adjacencies technologies Page 23
Slide 24: Key enablers supporting the commercial model in Chronic Care
We have built key enablers to support the commercial model in our Chronic Care businesses Commercial model Key enablers Direct Businesses Superior, clinically differentiated products Coloplast Consumer Care Consumer Clinical preference Data and digital tools preference Direct to Consumer Data & Digi
Slide 25: Direct business in Chronic Care drives growth
Direct business in Chronic Care serving consumers drives improved outcomes and is a vital component of our growth Direct presence in top 5 markets and strategic rationale Coloplast Care presence 1 Control and continuity of product supply ~30% MS ~10% MS ~5% MS +30 countries 2 Target the full value p
Slide 26: Clinical Performance Program to tackle biggest user issues
We have initiated a very ambitious Clinical Performance Program to tackle the biggest issues users face What really matters to people using catheters? What really matters to people living with a stoma? 45 %* of users describe UTIs are their 93 % worry about leakage2 greatest challenge in life1 * Peo
Slide 27: Progress across the Clinical Performance Program
We have made significant progress across the Clinical Performance Program Progress as of today Strive25 strategy period ends in 2025 Additional pilot study to further test the Product launch Digital ostomy technology in broader setup expected in first solution Pilot studies conducted with successful
Slide 28: Profitability supported by scalability and efficiency gains
Profitability supported by scalability and efficiency gains enabling additional investments within distribution and R&D Gross margin development, in % of revenue Cost item Development, in % of revenue +0.6%-points 28.1 28.7 29.0 28.7 27.6 28-30 Distribution - 0.1%-points 68.1 67.3 67.7 68.0 67.7 +0.
Slide 29: Automation, procurement and scale in Global Operations
Automation, procurement and scale are key to bringing Global Operations to the next level 1. Automation to mitigate growth in blue-collar FTE >1,000 DKK ~450m 10% ~800 CAPEX investment over # of FTE release ~500 through automation ~200 four years (19/20 – 22/23) Salary1 19/20 20/21 21/22 22/23 (Dire
Slide 30: Global Business Support and IT landscape
A global Business Support and IT landscape enables Coloplast to scale faster and more efficiently Global Business Services Global business services handle the majority of all global support % of group processes 100% ~90% 100% IT infrastructure Finance/ Master Data Global Business & support accountin
Slide 31: EBIT margin development drivers
EBIT margin development continues to be a function of growth, scalability, cost discipline and investment activity EBIT margin (%) Future drivers of EBIT margin ILLUSTRATIVE EBIT will be positively impacted by: + Leverage effect on fixed costs e.g. >30% distribution, admin and R&D costs ~31% especia
Slide 32: Continued strong free cash flow during Strive25
Continued strong development in free cash flow during the Strive25 strategy period Taxation Net working capital CAPEX(2) Reported tax rate Net working capital in % revenue Depreciation in % of revenue CAPEX DKKm CAPEX in % of revenue 6% 6% 5% 4% 4% 4% 5% 4% 4% 4% 4% 4% 23% 24% 24% ~24% 931 23% 23% 2
Slide 33: Attractive cash returns despite large investments
We will continue to provide attractive cash returns despite large investments in commercial and expansion activities Coloplast cash distribution to investors Comments • Coloplast returns excess liquidity to Dividends paid out in the year (mDKK) (1) Share buy-back (DKKm) Pay-out ratio (%) (2) shareho
Slide 34: In sum, stable shareholder returns
In sum, we believe Coloplast can continue to deliver stable shareholder returns through ... 32% Comments • Stable market trends in our Chronic Care business • Strong Coloplast Care retention program and innovative DtC 10% activities 9% 5% • Increased focus on growing the business outside Europe • Ad
Slide 35: Appendices
Leading intimate healthcare Appendices
Slide 36: The Coloplast share (COLO-B.CO)
The Coloplast share (COLO-B.CO) Share Capital Ownership Coloplast share listed on Nasdaq Copenhagen since 1983 ~200 billion DKK (~33 billion USD) market cap @ ~930 DKK per 11% share (incl. A shares) 4% 2% Two share classes: 46% • 18m A shares carry 10 votes (family) • 198m B shares carry 1 vote (fre
Slide 37: Capital structure
Capital structure Comments Net interest bearing debt • Overall policy is that excess liquidity is returned to shareholders through a 0.1x 0.1x 0.1x 0.2x combination of dividends and share buy- backs -0.2x • Interest bearing debt will be raised in connection with a major acquisition or other special
Slide 38: Key Value Ratios
Key Value Ratios Profitability drivers Free Cash Flow drivers 32.7 32.3 36.6 36.2 36.7 31.7 31.9 32.0 32.3 36.3 34.7 34.6 28.1 28.7 29.0 28.7 28.1 27.6 23.8 25.2 24.2 23.4 23.6 23.4 4.2 5.9 3.8 4.0 4.0 4.1 3.9 5.0 4.4 4.4 4.1 3.5 3.5 3.7 3.9 3.9 3.8 3.9 15/16 16/17 17/18 18/19 19/20 YTD 18/19 YTD 15
Slide 39: Revenue development by business area
Coloplast revenue development by business area Ostomy Care Interventional Urology 13 7,166 7,538 10 10 6,291 6,643 8 10 6 10 7 8 9 9 5 7 6 1,641 1,740 1,970 1,835 6 6 536 5 7 6 5 6 1,932 0 1 -7 16/17 17/18 18/19 19/20 YTD 20/21 16/17 17/18 18/19 19/20 YTD 20/21 Continence Care Wound & Skin Care 6,81
Slide 40: Revenue development by geography and total
Coloplast revenue development by geography and total Europe Other Developed Markets 10,573 10,820 9,394 9,941 15 16 11 16 11 6 6 6 8 7 5 2 2,737 3,642 3,791 4,380 4,644 2 0 2 5 6 2 1,174 0 4 5 16/17 17/18 18/19 19/20 YTD 20/21 16/17(1) 17/18) 18/19 19/20 YTD 20/21 Emerging Markets Coloplast group 17
Slide 41: Segment operating profit
Segment operating profit (Excludes shared/non-allocated costs) Chronic Care Interventional Urology Wound & Skin Care Ostomy and Continence Care 46 59 59 60 41 40 41 40 42 57 57 37 244 39 2,193 35 2,047 2,168 2,092 2,011 199 197 179 248 238 239 25 225 230 79 Q1 19/20 Q2 19/20 Q3 19/20 Q4 19/20 Q1 20/
Slide 42: Exchange rate exposure and hedging policy
Exchange rate exposure FY 2020/21 and hedging policy Revenue FX exposure 2020/21(1) 12 months exposure from 10% initial exchange rate drop(1) Other 17% -410 USD -170 EUR 36% -280 CNY, JPY, AUD, BRL & ARS 13% GBP -190 HUF 0 100 14% GBP 20% Revenue (DKKm) EBIT (DKKm) USD Foreign exchange rate guidance
Slide 43: US Mesh litigation – financial impact
US Mesh litigation – Overview of financial impact P&L Balance Cash flow Assets Actual/Expected cash flow, DKKbn 13/14 14/15 15/16 16/17 17/18 18/19 19/20 Restricted cash, DKKbn 0.5 0.5 EBIT (before special items) 4,147 4,535 4,846 5,024 5,091 5,556 5,854 Special items -1,000 -3,000 - 750 0 0 -400 -
Slide 44: Health reform landscape
Health reform landscape Europe Rest of World • Greece: Reimbursement pressure on all BAs • U.S.: Reimbursement pressure on OC and CC (Managed Care) • Germany: Reimbursement pressure on WC • Brazil: Macroeconomic and political challenges • Netherlands: Reimbursement pressure on OC and CC • Russia: Ma
Slide 45: CARE helps increase retention and compliance
CARE helps us increase retention and improve product compliance We co-develop CARE content with CARE is a personal and “high- Global program with shared local clinicians touch” program infrastructure Advisors available on phone Clinically validated content and call protocol - ERP Website with reliab
Slide 46: DtC marketing program reaches into the community
With our DtC marketing program we reach into the community We operate in numerous channels to expose our service …and with the reach we get several benefits and product offering… Expose innovative products Ensure product accessibility Ensure successful experience Page 46
Slide 47: Generic model for distribution and reimbursement
The generic model for distribution and reimbursement of our products Prescription & Insurance Product Payer Reimbursement price Distribution Prescription & Insurance Consumer $ Product . Page 47
Slide 48: Interventional Urology's revenue is balanced
Interventional Urology’s revenue is balanced geographically and across the four business areas Interventional Urology at a Glance ~15% market share in global market of DKK 12-13bn market FY 18/19 growing 3-5% annually 11% Coloplast position, FY 18/19 Endourology Men’s Health Women’s Health Bladder H
Slide 49: Select products
Coloplast Interventional Urology is split into four business areas MEN’S WOMEN’S SPECIALTY ENDOUROLOGY HEALTH HEALTH INTERVENTIONS • Erectile Dysfunction • Stress Urinary Incontinence • Stone Management • Bladder Drainage • Male Incontinence (SUI) • Transurethral • Benign prostatic hyperplasia • Tes
Slide 50: Strong presence in categories with room to capture share
We have a strong presence in our categories but there is room to capture market share Coloplast Share Competitive Share Men’s Health Women’s Health Endourology1 Bladder Health & Surgery1 <5% 30-35% <5% 35-45% 35-45% 10-15% 15-20% Inflatable Penile Male Stress urinary Pelvic organ Prosthesis (IPP) in
Slide 51: Coloplast acquires Nine Continents Medical Inc
Coloplast acquires Nine Continents Medical Inc, an early stage company in the large over-active bladder segment Over-active bladder market Company and product description • Over-active bladder (OAB) is a condition that causes a frequent and • Nine Continents Medical Inc is an early stage company pio
Slide 52: Global Advanced Wound Care market remains large and growing
The global Advanced Wound Care market remains large and growing despite a challenging 19/20 The Advanced Wound Care market remains a significant Silicone Foams and Gelling Fibers are the two biggest value pool and is expected to grow despite the pandemic categories and grow faster than the market Ma
Slide 53: The Wound & Skin Care 2025 strategic plan
The Wound & Skin Care 2025 strategic plan Scale our China business Build on positive momentum in EU by strengthening our commercial in silicone and 3DFit Technology and foundation and accelerate in silicone increase share of voice in selected with 3DFit Technology markets Scale our US business in Ac
Slide 54: Innovation drives US Ostomy Care growth
In US Ostomy Care, innovation is the biggest growth driver and we continue to win across patient pathway We have gained significant share over the last Innovation is a key driver, and we will continue to expand our offering years of high-quality products Bags & Plates acute share SenSura® Mio portfo
Slide 55: Investing up to DKK 250m in sustainable development
We are investing up to DKK 250m1 over the next 5 years to support sustainable environmental development Key Sustainability Targets 2025 Scope 1+2 emissions2 Renewable energy Company cars are Reduce business travel3 electrical Reducing emissions 100% 67% -10% while being a growth company 50% 6% 0% 1%
Slide 56: Reducing emissions while growing organically
We are committed to reducing emissions while growing 7-9% organically 2025 target 2025 target 0 100% 7% Emissions from scope Renewable energy 6% 1 +2 2025 target 13% Our greenhouse 2025 target 5% gas emissions in • Reductions dependent on how much the Limit on goods 19/20* impact of product and pack
Slide 57: Commitment to responsible operations
We continue our strong commitment to responsible operations Key Sustainability Targets 2025 100% 2.0 Responsible White-collars trained in operations Code of Conduct Loss-time injury rate* is our core values 30% 75% Female representation of teams (Director and above) at VP+ levels meet diverse team t
Slide 58: Introducing Ostomy Care
Introducing Ostomy Care Disease areas Key products Distribution of • Colorectal cancer (est. 45%) revenues* • Bladder cancer (est. 10%) • Diverticulitis (est. 15%) Urostomy • Inflammatory bowel disease (est. 10%) Ileostomy • Other (est. 20%) Colostomy Customer groups • Nurses, mainly stoma care nurs
Slide 59: Introducing Ostomy Care Supporting Products
Introducing Ostomy Care Supporting Products Market fundamentals Key products Brava® is a range of ostomy supporting products • Market size of DKK ~3bn designed to reduce leakage or care for skin, to make • Market growth of 6-8% • Market share 35-40% Brava® Protective Seal our end-users feel secure.
Slide 60: Introducing Continence Care
Introducing Continence Care Disease areas Key products Distribution of • Spinal Cord Injured, SCI revenues • Spina Bifida, SB • Multiple Sclerosis, MS Intermittent catheters • Benign prostatic hyperplasia, BPH & prostatectomy patients Urine bags • Elderly Male ext. catheters Bowel management CC Othe
Slide 61: Introducing Bowel Management
Introducing Bowel Management Disease areas Market dynamics Faecal incontinence + Growing awareness (management products only) + Huge underpenetrated and Customer groups unserved population • Spinal Cord Injured, SCI + New devices addressing the many • Spina Bifida, SB unmet needs • Multiple Sclerosi
Slide 62: Introducing Interventional Urology
Introducing Interventional Urology Treatment (surgical) of urological disorders Disease areas Key products Distribution of revenues • Urinary incontinence • Pelvic organ prolapse Men’s health • Erectile dysfunction Women’s health • Enlarged prostate • Kidney and urinary stones Single use devices Cus
Slide 63: Introducing Wound Care
Introducing Wound Care Disease areas Key products Distribution of revenues Chronic wounds (WSC) • Leg ulcers Biatain® range • Diabetic foot ulcers Comfeel® range • Pressure ulcers Skin Care Wound Care other Customer groups Contract manufacturing & call points Hospitals Biatain® Silicone, incl. Sizes
Slide 64: Introducing Skin Care
Introducing Skin Care Disease areas Key products Product mix • Moisture associated skin damage Protectants & Antifungals • Incontinence Cleansing/Bathing • Skin folds & obesity Moisturizers • Prevention of skin impairments Textile SC Other Customer groups & call points Sween® EasiCleanse Bath® Hospi
Slide 65: Product market for US Skin Care
Product market for US Skin Care Market drivers/limiters US Skin Care at a glance + Aging and obese population • US market size estimated at DKK + CMS Value Based Purchasing 4-5bn with 2-4% growth + Increased focus on prevention + Increased importance of utilization • Market share: 10-15% management
Slide 66: The Coloplast organisation
The Coloplast organisation Coloplast Group Chronic Care Strategic Business Units Chronic Care Strategic Business Units Ostomy Care Continence Care Wound & Skin Care Interventional Urology R&D Marketing Sales R&D Marketing Marketing Operations Sales Regions Global Operations Global Business Support F
Slide 67: Coloplast Executive Leadership Team
Coloplast Executive Leadership Team Kristian Villumsen President, CEO • Born 1970 • With Coloplast since 2008 Nicolai Buhl Andersen Anders Lonning-Skovgaard Paul Marcun Camilla G. Møhl Allan Rasmussen EVP, Innovation EVP, CFO EVP, Growth SVP, People & Culture EVP, Operations • Born 1969 • Born 1972
Slide 68: Income statement
Income statement DKKm Q1 2019/20 Q1 2020/21 Change Revenue 4,712 4,738 1% Gross profit 3,212 3,206 0% SG&A costs -1,586 -1,495 -6% R&D costs -169 -186 10% Other operating income/expenses 15 11 -27% Operating profit (EBIT) 1,472 1,536 4% Net financial items -54 -41 nm Tax -326 -359 10% Net profit 1,0
Slide 69: Balance sheet
Balance sheet DKKm 31 Dec 2019 31 Dec 2020 Change Balance, total 13,223 14,926 13% Assets Non-current assets 6,862 8,286 21% Current assets 6,361 6,640 4% of which: Inventories 1,917 2,231 16% Trade receivables 2,982 2,916 -2% Restricted cash 13 0 -100% Marketable securities, cash, and cash equivale
Slide 70: Cash flow
Cash flow DKKm Q1 2019/20 Q1 2020/21 Change EBIT 1,472 1,536 4% Depreciation and amortisation 208 202 -3% Change in working capital 321 246 -23% Net interest payments -65 4 -106% Paid tax -871 -728 -16% Other -35 -48 37% Cash flow from operations 1,030 1,212 18% Investment in intangibles1) -18 -975
Slide 71: Manufacturing setup
Manufacturing setup Production by country (Volume)¹ 4% Hungary 11% 0% 2% Mørdrup Tatabánya China Minneapolis Sarlat Nyirbátor US/France Mankato Denmark Zhuhai Costa Rica Costa Rica 83% COGS by cost type² 10% 18% Salary - Direct 12% Salary - Indirect 8% Materials (RM &SFG) Innovation & Specialised Pr
Slide 72: Production sites
Production sites Hungary China Tatabánya Zhuhai • Ostomy care products • Continence care products • Adhesives • Ostomy care products • Continence care products • Machine building • Interventional Urology products • Number of employees in production: ~1,000 • Number of employees in production: ~1,950
Slide 73: Production sites
Production sites Denmark US Mørdrup Minneapolis • Pilot development work Ostomy care, • Interventional Urology products Continence care and Wound care • Number of employees in production: ~100 • Adhesives production • Number of employees in production: ~150 France Mankato • Skin care products Sarlat
Slide 74: Coloplast Sponsored Level 1 ADR programme
Coloplast Sponsored Level 1 ADR programme Coloplast Sponsored ADR Programme Benefits of a Coloplast ADR programme to US Investors: • Coloplast has established a sponsored ADR programme in the US, as a Symbol CLPBY service to US investors by offering an alternative way to trade Coloplast shares, whil
Slide 75: Contact Investor Relations
Contact Investor Relations Holtedam 1 DK-3050 Humlebæk Denmark Ellen Bjurgert Hannah Katrine Larsen Sophia Mastrell Vice President, Investor Relations Investor Relations Coordinator & PA Student Assistant, Investor Relations Tel. direct: +45 4911 3376 Tel. direct: +45 4911 3616 Tel. direct: +45 4911
Slide 76: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /